Reduced Factor V Concentration and Altered FV1/FV2 Ratio do not fully Explain R2-associated APC-resistance

José W. P. Govers-Riemslag; Elisabetta Castoldi; Gerry A. F. Nicolaes; Guido Tans; Jan Rosing

doi:10.1055/s-0037-1613236

Thrombosis and Haemostasis, Inhaltsverzeichnis

Thromb Haemost 2002; 88(03): 444-449
DOI: 10.1055/s-0037-1613236

Review Article

Schattauer GmbH

Reduced Factor V Concentration and Altered FV1/FV2 Ratio do not fully Explain R2-associated APC-resistance

José W. P. Govers-Riemslag

¹Department of Biochemistry, Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, The Netherlands

,

Elisabetta Castoldi

¹Department of Biochemistry, Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, The Netherlands

,

Gerry A. F. Nicolaes

¹Department of Biochemistry, Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, The Netherlands

,

Guido Tans

¹Department of Biochemistry, Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, The Netherlands

,

Jan Rosing

¹Department of Biochemistry, Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, The Netherlands

› Institutsangaben

Abstract

Summary

Carriership of the factor V (FV) R2 haplotype is associated with mild APC-resistance, moderately reduced FV levels and a relative increase of the more thrombogenic FV isoform, FV₁. Since low FV levels and increased FV₁ can theoretically cause APC-resistance, we investigated whether these alterations can quantitatively account for R2-associated APC-resistance. In order to determine the effect of FV concentration and FV isoform composition on the APC-response, we reconstituted FV-deficient plasma with purified FV₁ and FV₂ in different molar ratios and to varying FV concentrations. APC sensitivity ratios (APCsr) were determined with the Coatest^® APC^TM Resistance V, which probes the effect of APC on both FV-a and FVIIIa-inactivation, and with the Immunochrom^® APC response test, which only quantifies the effect of APC on FVIII(a)-inactivation. In both assays, low FV concentrations and/or high relative amounts of FV₁ rendered plasma samples more resistant to APC. APCsr were also determined in FVdeficient plasma reconstituted with purified FV at levels and isoform ratios observed in R2-homozygotes (98% FV, 42% FV₁) and agematched controls (119% FV, 26% FV₁). In both tests the APCsr of reconstituted control plasma was the same as that of plasma from controls, whereas reconstituted R2-plasma was less APC-resistant than plasma from homozygous carriers of the R2 haplotype. We conclude that the low FV levels and altered FV isoform ratio cannot fully explain R2-associated APC-resistance.

Keywords

APC-resistance - FV isoforms - R2 haplotype - factor VIII

Volltext

Referenzen

References
1 Walker FJ, Fay PJ. Regulation of blood coagulation by the protein C system. FASEB J 1992; 06: 2561-7.
2 Walker FJ. Regulation of activated protein C by a new protein A possible function for bovine protein S. J Biol Chem 1980; 255: 5521-4.
3 Shen L, Dahlbäck B. Factor V and protein S as synergistic cofactors to activated protein C in degradation of factor VIIIa. J Biol Chem 1994; 269: 18735-8.
4 Váradi K, Rosing J, Tans G, Pabinger I, Keil B, Schwarz HP. Factor V enhances the cofactor function of protein S in the APC-mediated inactivation of factor VIII: influence of the factor VR506Q mutation. Thromb Haemost 1996; 76: 208-14.
5 Dahlbäck B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: Prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA 1993; 90: 1004-8.
6 Koster T, Rosendaal FR, de Ronde H, Briët E, Vandenbroucke JP, Bertina RM. Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study. Lancet 1993; 342: 1503-6.
7 Svensson PJ, Dahlbäck B. Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med 1994; 330: 517-22.
8 Bertina RM, Koeleman BPC, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, van der Velden PA, Reitsma PH. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369: 64-7.
9 Nicolaes GAF, Tans G, Thomassen MCLGD, Hemker HC, Pabinger I, Váradi K, Schwarz HP, Rosing J. Peptide bond cleavages and loss of functional activity during inactivation of FVa and factor VaR506Q by activated protein C. J Biol Chem 1995; 270: 21158-66.
10 Kalafatis M, Bertina RM, Rand MD, Mann KG. Characterization of the molecular defect in factor VR506Q. J Biol Chem 1995; 270: 4053-7.
11 Thorelli E, Kaufman RJ, Dahlbäck B. Cleavage of factor V at Arg 506 by activated protein C and the expression of anticoagulant activity of factor V. Blood 1999; 93: 2552-8.
12 de Ronde H, Bertina RM. Laboratory diagnosis of APC-resistance: A critical evaluation of the test and the development of diagnostic criteria. Thromb Haemost 1994; 72: 880-6.
13 Simioni P, Girolami A. Homozygous factor V deficient patients show resistance to activated protein C whereas heterozygotes do not. Blood Coagul Fibrinolysis 1994; 05: 825-7.
14 Luddington R, Jackson A, Pannerselvam S, Brown K, Baglin T. The factor V R2 allele: risk of venous thromboembolism, factor V levels and resistance to activated protein C. Thromb Haemost 2000; 83: 204-8.
15 Henkens CMA, Bom VJJ, van der Meer J. Lowered APC-sensitivity ratio related to increased factor VIII-clotting activity. Thromb Haemost 1995; 74: 1198-9.
16 Laffan MA, Manning R. The influence of factor VIII on measurement of activated protein C resistance. Blood Coagul Fibrinolysis 1996; 07: 761-5.
17 Rosing J, Bakker HM, Thomassen MCLGD, Hemker HC, Tans G. Characterization of two forms of human factor Va with different cofactor activities. J Biol Chem 1993; 268: 21130-6.
18 Hoekema L, Nicolaes GAF, Hemker HC, Tans G, Rosing J. Human factor Va₁ and factor Va₂: Properties in the procoagulant and anticoagulant pathways. Biochemistry 1997; 36: 3331-5.
19 Nicolaes GAF, Villoutreix BO, Dahlbäck B. Partial glycosylation of Asn2181 in human factor V as a cause of molecular and functional heterogeneity Modulation of glycosylation efficiency by mutagenesis of the consensus sequence for N-linked glycosylation. Biochemistry 1999; 38: 13584-91.
20 Kim SW, Ortel TL, Quinn-Allen MA, Yoo L, Worfolk L, Zhai X, Lentz BR, Kane WH. Partial glycosylation at asparagine-2181 of the second Ctype domain of human factor V modulates assembly of the prothrombinase complex. Biochemistry 1999; 38: 11448-54.
21 Lunghi B, Iacoviello L, Gemmati D, di Iasio MG, Castoldi E, Pinotti M, Castaman G, Redaelli R, Mariani G, Marchetti G, Bernardi F. Detection of new polymorphic markers in the factor V gene: Association with factor V levels in plasma. Thromb Haemost 1996; 75: 45-8.
22 Bernardi F, Faioni EM, Castoldi E, Lunghi B, Castaman G, Sacchi E, Mannucci PM. A factor V genetic component differing from factor V R506Q contributes to the activated protein C resistance phenotype. Blood 1997; 90: 1552-7.
23 Castoldi E, Rosing J, Girelli D, Hoekema L, Lunghi B, Mingozzi F, Ferraresi P, Friso S, Corrocher R, Tans G, Bernardi F. Mutations in the R2 factor V gene affect the ratio between the two FV isoforms in plasma. Thromb Haemost 2000; 83: 362-5.
24 Alhenc-Gelas M, Nicaud V, Gandrille S, van Dreden P, Amiral J, Aubry ML, Fiessinger J-N, Emmerich J, Aiach M. The factor V gene A4070G mutation and the risk of venous thrombosis. Thromb Haemost 1999; 82: 193-7.
25 Faioni EM, Franchi F, Bucciarelli P, Margaglione M, De Stefano V, Castaman G, Finazzi G, Mannucci PM. Coinheritance of the HR2 haplotype in the factor V gene confers an increased risk of venous thromboembolism to carriers of factor V R506Q (factor V Leiden). Blood 1999; 94: 3062-6.
26 Margaglione M, Bossone A, Coalizzo D, D’Andrea G, Brancaccio V, Ciampa A, Grandone E, Di Minno G. FV HR2 haplotype as additional inherited risk factor for deep vein thrombosis in individuals with a high-risk profile. Thromb Haemost 2002; 87: 32-6.
27 Aras O, Hanson NQ, Tsai MY, Key NS. Is homozygosity for the HR2 haplotype a risk factor for venous thromboembolism?. Thromb Haemost 2002; 87: 173-4.
28 Akar N, Yilmaz E, Akar E, Deda G, Sipahi T. Factor V (His 1299 Arg) in young Turkish patients with cerebral infarct. Haemostasis 2000; 30: 118-22.
29 de Visser MCH, Guasch JF, Kamphuisen PW, Vos HL, Rosendaal FR, Bertina RM. The R2 haplotype of factor V: effects on factor V levels, normalized activated protein C sensitivity ratios and the risk of venous thrombosis. Thromb Haemost 2000; 83: 577-82.
30 Doggen CJM, de Visser MCH, Vos HL, Bertina RM, Manger VCats, Rosendaal FR. The HR2 haplotype of factor V is not associated with the risk of myocardial infarction. Thromb Haemost 2000; 84: 815-8.
31 Ameziane N, Lebret D, Combe A, Aumont M-C, de Prost D. No association between the R2 factor V gene and acute coronary events. Thromb Haemost 2001; 85: 566-7.
32 Hoekema L, Castoldi E, Tans G, Girelli D, Gemmati D, Bernardi F, Rosing J. Functional properties of factor V and factor Va encoded by the R2 gene. Thromb Haemost 2001; 85: 75-81.
33 Tans G, Rosing J, Thomassen MC, Heeb MJ, Zwaal RF, Griffin JH. Comparison of anticoagulant and procoagulant activities of stimulated platelets and platelet-derived microparticles. Blood 1991; 77: 2641-8.
34 van Rijn JL, Govers-Riemslag JW, Zwaal RF, Rosing J. Kinetic studies of prothrombin activation: Effect of factor Va and phospholipids on the formation of the enzyme-substrate complex. Biochemistry 1984; 23: 4557-64.
35 Hoekema L, Rosing J, Tans G. An assay to quantify the two plasma isoforms of factor V. Thromb Haemost 2000; 84: 1066-71.
36 Váradi K, Moritz B, Lang H, Bauer K, Preston E, Peake I, Rivard GE, Keil B, Schwarz HP. A chromogenic assay for activated protein C resistance. Br J Haematol 1995; 90: 884-91.
37 Samama MS, Gouin-Thibault I, Trossaert M, van Dreden P, Combot C, Amiral J, Horellou MH, Conard J. Low levels of protein S activity in factor V depleted plasma used in APC resistance test. Thromb Haemost 1998; 80: 715-6.
38 Williamson D, Brown K, Luddington R, Baglin C, Baglin T. Factor V Cambridge: a new mutation (Arg306 →Thr) associated with resistance to activated protein C. Blood 1998; 91: 1140-4.
39 Chan WP, Lee CK, Kwong YL, Lam CK, Liang R. A novel mutation of Arg306 of factor V gene in Hong Kong Chinese. Blood 1998; 91: 1135-9.
40 Lu D, Kalafatis M, Mann KG, Long GL. Comparison of activated protein C/protein S-mediated inactivation of human factor VIII and factor V. Blood 1996; 87: 4708-17.
41 Thorelli E, Kaufman RJ, Dahlbäck B. The C-terminal region of the factor V B-domain is crucial for the anticoagulant activity of factor V. J Biol Chem 1998; 273: 16140-5.